Paul Tudor Jones Cogent Biosciences, Inc. Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 16,819 shares of COGT stock, worth $134,552. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,819Holding current value
$134,552% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding COGT
# of Institutions
190Shares Held
104MCall Options Held
157KPut Options Held
439K-
Kynam Capital Management, LP Princeton, NJ9.11MShares$72.8 Million4.5% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$58.3 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$55.7 Million8.87% of portfolio
-
Commodore Capital LP New York, NY6.88MShares$55.1 Million5.38% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA6.23MShares$49.8 Million9.76% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $526M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...